Global Erectile Dysfunction Market Market Companies
- Teva Pharmaceutical Industries Limited
- Bonro Medical
- Endo International Plc.
- Eli Lilly and Company
- Futura Medical
- Augusta Medical Systems LLC
- Pfizer
- Cristalia Produtos Quimicos Farmaceuticos Ltda.
- Premedon
- SK Chemicals
- Post-T-Vac Medical
- Bayer AG
- VIVUS Inc.
- Boston Scientific Corp.
- Zephyr Surgical Implants (ZSI)
- Apricus Biosciences Inc.
- Coloplast A/S
Recent News:
- In May 2022, Spanish specialty pharmaceutical company Laboratorios Rubio S.A. sold its Bandol brand of prescription drugs to Aspargo Laboratories, Inc.
- In March 2022, Lupine received FDA approval for its ANDA for sildenafil (10 mg/mL oral suspension) to market a generic equivalent of Viatris Specialty LLC's Revatio for suspension drink. Access to affordable generic products increases patient compliance, thereby increasing the consumer base and market revenue.
- In September 2021, iX Biopharma, through its wholly owned subsidiary, entered into an agreement with CRPCG for the license, supply and distribution of Wafesil, a sublingual blister pack of sildenafil for the treatment erectile dysfunction in men, in China.
- In September 2021, Almus announced the launch of Almus Erectile Dysfunction Relief 50 mg film-coated tablets to the UK pharmaceutical market.